SCYNEXIS, Inc. is a drug development company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapeutic areas.
We are developing our lead product candidate, SCY-078, as a novel and structurally distinct triterpenoid glucan synthase inhibitor. SCY-078
is in Phase 2 clinical development as an oral and intravenous drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections.